137 related articles for article (PubMed ID: 16150806)
1. Is the gefitinib plus trastuzumab combination feasible in breast cancer patients?
Normanno N; Campiglio M; Perrone F; De Luca A; Menard S
Ann Oncol; 2005 Oct; 16(10):1709. PubMed ID: 16150806
[No Abstract] [Full Text] [Related]
2. A Phase I/II Trial of trastuzumab and gefitinib in patients with Metastatic Breast Cancer that overexpresses HER2/neu (ErbB-2).
Moulder SL; Arteaga CL
Clin Breast Cancer; 2003 Jun; 4(2):142-5. PubMed ID: 12864943
[No Abstract] [Full Text] [Related]
3. Combined anti-EGF receptor and anti-HER2 receptor therapy in breast cancer: a promising strategy ready for clinical testing.
Baselga J
Ann Oncol; 2002 Jan; 13(1):8-9. PubMed ID: 11863116
[No Abstract] [Full Text] [Related]
4. Induction of remission in a patient with metastatic breast cancer refractory to trastuzumab and chemotherapy following treatment with gefitinib ('Iressa', ZD1839).
Schneeweiss A; Kolay S; Aulmann S; Von Minckwitz G; Torode J; Koehler M; Bastert G
Anticancer Drugs; 2004 Mar; 15(3):235-8. PubMed ID: 15014356
[TBL] [Abstract][Full Text] [Related]
5. ECOG E1100: a phase II trial of trastuzumab and gefitinib in patients with metastatic breast cancer that overexpress HER2/neu (erbB-2).
Clin Adv Hematol Oncol; 2003 Apr; 1(4):237. PubMed ID: 16224413
[No Abstract] [Full Text] [Related]
6. [Combined chemotherapy with molecular-targeted agent for breast cancer].
Ito Y; Miura H
Gan To Kagaku Ryoho; 2008 May; 35(5):731-6. PubMed ID: 18487908
[TBL] [Abstract][Full Text] [Related]
7. Dual-agent molecular targeting of the ErbB2 receptor: killing one bird with two stones.
Hirte HW; Hotte SJ
J Clin Oncol; 2008 Jul; 26(20):3301-2. PubMed ID: 18490647
[No Abstract] [Full Text] [Related]
8. Dose-dense chemotherapy with trastuzumab is an appropriate option.
Dang C; Norton L; Hudis C
J Clin Oncol; 2008 Jul; 26(21):3655-6; author reply 3656. PubMed ID: 18640949
[No Abstract] [Full Text] [Related]
9. Multitargeted therapy in estrogen receptor-positive, human epidermal growth factor receptor-2-positive breast cancer.
Nahleh ZA; Jazieh AR
Am J Clin Oncol; 2005 Dec; 28(6):631-3. PubMed ID: 16317277
[No Abstract] [Full Text] [Related]
10. Hints of future progress for HER-2 breast cancer.
Twombly R
J Natl Cancer Inst; 2011 Apr; 103(7):535-7. PubMed ID: 21436059
[No Abstract] [Full Text] [Related]
11. Integrating biological agents into systemic therapy of breast cancer: trastuzumab, lapatinib, bevacizumab.
Eniu A
J BUON; 2007 Sep; 12 Suppl 1():S119-26. PubMed ID: 17935269
[TBL] [Abstract][Full Text] [Related]
12. Highlights From ECCO 13-The European Cancer Conference Paris, France October 30 to November 3, 2005.
Clin Breast Cancer; 2005 Dec; 6(5):380-4. PubMed ID: 16381621
[No Abstract] [Full Text] [Related]
13. Integration of trastuzumab into adjuvant systemic therapy of breast cancer: ongoing and planned clinical trials.
Hortobagyi GN; Perez EA
Semin Oncol; 2001 Oct; 28(5 Suppl 16):41-6. PubMed ID: 11706395
[TBL] [Abstract][Full Text] [Related]
14. Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer.
Storniolo AM; Pegram MD; Overmoyer B; Silverman P; Peacock NW; Jones SF; Loftiss J; Arya N; Koch KM; Paul E; Pandite L; Fleming RA; Lebowitz PF; Ho PT; Burris HA
J Clin Oncol; 2008 Jul; 26(20):3317-23. PubMed ID: 18490651
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab and breast cancer. Are we just beyond the prologue of a fascinating story?
Puglisi F; Piccart M
Onkologie; 2005 Nov; 28(11):547-9. PubMed ID: 16249638
[No Abstract] [Full Text] [Related]
16. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
[TBL] [Abstract][Full Text] [Related]
17. Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB Trial).
Guarneri V; Frassoldati A; Piacentini F; Jovic G; Giovannelli S; Oliva C; Conte P
Clin Breast Cancer; 2008 Apr; 8(2):192-4. PubMed ID: 18621618
[No Abstract] [Full Text] [Related]
18. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction.
Warburton C; Dragowska WH; Gelmon K; Chia S; Yan H; Masin D; Denyssevych T; Wallis AE; Bally MB
Clin Cancer Res; 2004 Apr; 10(7):2512-24. PubMed ID: 15073131
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab plus chemotherapy: convincing survival benefit or not?
Vogel CL; Tan-Chiu E
J Clin Oncol; 2005 Jul; 23(19):4247-50. PubMed ID: 15911863
[No Abstract] [Full Text] [Related]
20. Never use anthracyclines with trastuzumab: it is time to reconsider the taboo.
Gianni L
Breast Cancer Res Treat; 2009 Oct; 117(3):599-601. PubMed ID: 19387827
[No Abstract] [Full Text] [Related]
[Next] [New Search]
